Serum Albumin in Acute Coronary Syndrome

Launched by SOHAG UNIVERSITY · Dec 6, 2024

Keywords

ClinConnect Summary

This clinical trial is exploring how levels of a protein called serum albumin can predict short-term outcomes for patients with Acute Coronary Syndrome (ACS), which is a serious condition that affects the heart. Researchers want to understand if measuring serum albumin levels can help identify patients who might be at higher risk for complications shortly after being admitted to the hospital.

To be eligible for this study, participants should be at least 18 years old and have been diagnosed with ACS while in the emergency department or coronary care unit. However, individuals with certain health conditions, like chronic liver disease, or those receiving treatments that might alter serum albumin levels are not eligible. This trial is not currently recruiting participants, but once it starts, those who join can expect to provide some medical information and undergo tests to measure their serum albumin levels as part of their care.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients aged 18 years or older who were admitted to the emergency department or coronary care unit with a diagnosis of acute coronary syndrome (ACS) will be eligible for inclusion.
• Exclusion Criteria:
• • 1. Patients with a history of chronic liver disease, nephrotic syndrome, or other conditions known to affect serum albumin levels.
• • 2. Patients receiving albumin infusions or other treatments that could potentially interfere with serum albumin levels.
• • 3. Patients with incomplete medical records or missing laboratory data.
• • 4. Patients who declined to participate in the study.